Re-examination Study for General Drug Use to Assess the Safety and Efficacy of ISENTRESS in Usual Practice.
Phase of Trial: Phase IV
Latest Information Update: 24 Jul 2015
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co
- 10 Jun 2017 Biomarkers information updated
- 29 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.